CA05156V1022
CA05156V1022
Aurinia Pharmaceuticals Inc
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 2.22B EUR | 2.26B EUR | 1.94B EUR | 2.11B EUR |
Enterprise Value | 1.78B EUR | 2.14B EUR | 1.97B EUR | 2.11B EUR |
Valuation Multiples | ||||
Trailing P/E | 7.3x | 7.18x | 6.5x | 8x |
Forward P/E | 15.61x | -- | -- | -- |
Price to Sales | 7.11x | 7.24x | 6.5x | 9.57x |
Price to Book | 3.6x | 3.67x | 3.41x | 3.63x |
EV/Revenue | 5.71x | 6.87x | 6.59x | 9.54x |
EV/EBITDA | 9.89x | 11.64x | 12.48x | 19.53x |
Price to FCF (P/FCF) | 14.99x | 12.88x | 11.63x | 15.74x |
EV/FCF | 12.04x | 12.22x | 11.8x | 15.7x |
FCF Yield | 6.67% | 7.76% | 8.6% | 6.35% |